NCT05658601Completed
A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
SWITCH - ITA A Multicentre, Single Country, Prospective Non Interventional Observational Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod, in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated According to Clinical Practice.
Source: ClinicalTrials.gov · Last updated 1 Oct 2025
Brief summary (registry, in English)
The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 104 (actual)
- First submitted
- 12 Dec 2022
- Start date
- 14 Jul 2023
- Primary completion date
- 3 Jul 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Multiple sclerosis
- NCT number
- NCT05658601
What you commit to
- Study type: Observational
- Participants enrolled: 104
- From 14 Jul 2023 to the primary completion date, 3 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients participating in another clinical study with an investigational product if the study considers the switching behavior as an endpoint or objective
Other
- Patients with clinical forms of MS other than RRMS
- Patients unable to participate for various reasons
- Contraindications to ozanimod according to SmPC
- Other protocol-defined Inclusion/Exclusion Criteria apply.
Who the study is looking for
- Patients with RRMS according to 2017 revised McDonald criteria
- Patients who switched a previous first or second line DMT to ozanimod between 4 and 12 weeks before the enrollment
- Patient with a MRI performed within three months before the enrollment
- Patient eligible to ozanimod according to SmPC
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Isernia | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.